President, Chief Executive Officer, and Chairman of the Board
In it to honor my father’s experience with cancer.
Clay co-founded Seagen in 1998 with a vision to improve the lives of people with cancer by developing targeted therapies to treat major unmet needs. A scientist by training, he built a foundation based on a unique science-driven culture, successful drug discovery and development, and a passion for helping patients. Today, Seagen has three FDA-approved medicines and leads the field in antibody–drug conjugate (ADC) technology and development.
Prior to founding Seagen, Clay held positions at Bristol Myers Squibb Pharmaceutical Research Institute, the National Institutes of Health, and the National Cancer Institute. He has authored more than 70 publications and holds 15 patents. Clay has been recognized as an Ernst & Young Entrepreneur of the Year and the Dealmaker of the Year by the Puget Sound Business Journal.
Clay holds a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland. He serves as a member of the board of directors of Ultragenyx Pharmaceutical and Washington Roundtable.
You are leaving Seagen
You are now leaving Seagen site. Seagen does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave Seagen.com?